Literature DB >> 27352067

Does ponatinib cross the blood-brain barrier?

Muhammad B Abid1, Sanjay De Mel1.   

Abstract

Entities:  

Keywords:  Ph+ALL; T315I mutation; ponatinib; tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2016        PMID： 27352067     DOI： 10.1111/bjh.14222

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

Review 1.  c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's Disease.

Authors:  Dan Lindholm; Dan D Pham; Annunziata Cascone; Ove Eriksson; Krister Wennerberg; Mart Saarma
Journal:  Front Aging Neurosci       Date:  2016-10-26       Impact factor: 5.750

2.  Identification and targeting of an FGFR fusion in a pediatric thalamic "central oligodendroglioma".

Authors:  Joseph R Linzey; Bernard Marini; Kathryn McFadden; Adonis Lorenzana; Rajen Mody; Patricia L Robertson; Carl Koschmann
Journal:  NPJ Precis Oncol       Date:  2017-09-07

3.  Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.

Authors:  Eudocia Q Lee; Alona Muzikansky; Dan G Duda; Sarah Gaffey; Jorg Dietrich; Lakshmi Nayak; Ugonma N Chukwueke; Rameen Beroukhim; Lisa Doherty; Caroline Kane Laub; Debra LaFrankie; Brittney Fontana; Jennifer Stefanik; Sandra Ruland; Victoria Caruso; Jennifer Bruno; Keith Ligon; David A Reardon; Patrick Y Wen
Journal:  Cancer Med       Date:  2019-08-24       Impact factor: 4.452

4.  Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice.

Authors:  Karthik Ravi; Andrea Franson; Morgan J Homan; Holly Roberts; Manjunath P Pai; Zachary Miklja; Miao He; Bo Wen; Lydia L Benitez; Anthony J Perissinotti; Dale L Bixby; Carl Koschmann; Bernard L Marini
Journal:  Leuk Lymphoma       Date:  2021-03-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.